loading page

Impact of the UK COVID-19 pandemic on HbA1c testing and its implications for diabetes diagnosis and management
  • +8
  • David Holland,
  • Adrian Heald,
  • Mike Stedman,
  • Lewis Green,
  • Jonathan Scargill,
  • Christopher Duff,
  • Fahmy Hanna,
  • Pensee Wu,
  • Ian Halsall,
  • Neil Gaskell,
  • Anthony Fryer
David Holland
The Benchmarking Partnership
Author Profile
Adrian Heald
Salford Royal Hospitals NHS Trust
Author Profile
Mike Stedman
Res Consortium
Author Profile
Lewis Green
Whiston Hospital
Author Profile
Jonathan Scargill
Salford Royal Hopspital
Author Profile
Christopher Duff
University Hospitals of North Midlands
Author Profile
Fahmy Hanna
University Hospitals of North Midlands NHS Trust
Author Profile
Ian Halsall
Addenbrooke's Hospital
Author Profile
Neil Gaskell
Warrington and Halton Hospitals NHS Foundation Trust
Author Profile
Anthony Fryer
Keele University
Author Profile

Abstract

Our findings illustrate the widespread collateral impact of implementing measures to mitigate the impact of COVID-19 in people with, or being investigated for diabetes mellitus (DM). Ironically, failure to focus of the wider implications for people with DM and other groups with long-term conditions, may place them at increased risk of poor outcomes from SARS-CoV-2 infection itself, irrespective of the implications for their longer-term health prospects.

Peer review status:ACCEPTED

10 Dec 2020Submitted to International Journal of Clinical Practice
10 Dec 2020Submission Checks Completed
10 Dec 2020Assigned to Editor
11 Dec 2020Reviewer(s) Assigned
25 Dec 2020Review(s) Completed, Editorial Evaluation Pending
27 Dec 20201st Revision Received
28 Dec 2020Submission Checks Completed
28 Dec 2020Assigned to Editor
28 Dec 2020Reviewer(s) Assigned
28 Dec 2020Review(s) Completed, Editorial Evaluation Pending
03 Jan 2021Editorial Decision: Accept